Today, Jefferies Group Begins Coverage on TherapeuticsMD Inc (TXMD)

Today, Jefferies Group Begins Coverage on TherapeuticsMD Inc (TXMD)
Jefferies Group began coverage on shares of TherapeuticsMD Inc (NASDAQ:TXMD) in a research report released on Tuesday. The brokerage issued a buy rating and a $18.00 price target on the stock.

Separately, Oppenheimer Holdings Inc. initiated coverage on TherapeuticsMD in a report on Tuesday. They issued an outperform rating and a $12.00 price target on the stock.

TherapeuticsMD (NASDAQ:TXMD) opened at 7.15 on Tuesday. The firm has a 50-day moving average price of $6.26 and a 200 day moving average price of $7.34. TherapeuticsMD has a 52-week low of $4.39 and a 52-week high of $11.26. The stock’s market capitalization is $1.41 billion.

Hedge funds have recently made changes to their positions in the stock. Sanders Morris Harris Inc. increased its stake in shares of TherapeuticsMD by 18.9% in the third quarter. Sanders Morris Harris Inc. now owns 506,100 shares of the company’s stock valued at $3,446,000 after buying an additional 80,500 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $2,724,000. First Trust Advisors LP increased its stake in shares of TherapeuticsMD by 74.5% in the third quarter. First Trust Advisors LP now owns 90,707 shares of the company’s stock valued at $618,000 after buying an additional 38,723 shares during the period. Aperio Group LLC purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $164,000. Finally, TD Asset Management Inc. increased its stake in shares of TherapeuticsMD by 3.5% in the third quarter. TD Asset Management Inc. now owns 551,300 shares of the company’s stock valued at $3,754,000 after buying an additional 18,400 shares during the period.

About TherapeuticsMD

Related posts

Leave a Comment